Key Insights

Highlights

Success Rate

77% trial completion

Published Results

14 trials with published results (10%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.6%

12 terminated out of 139 trials

Success Rate

77.4%

-9.2% vs benchmark

Late-Stage Pipeline

4%

6 trials in Phase 3/4

Results Transparency

34%

14 of 41 completed with results

Key Signals

14 with results77% success12 terminated

Data Visualizations

Phase Distribution

114Total
Not Applicable (61)
Early P 1 (8)
P 1 (7)
P 2 (32)
P 3 (5)
P 4 (1)

Trial Status

Completed41
Recruiting36
Active Not Recruiting27
Terminated12
Unknown7
Not Yet Recruiting6

Trial Success Rate

77.4%

Benchmark: 86.5%

Based on 41 completed trials

Clinical Trials (139)

Showing 20 of 20 trials
NCT02465060Phase 2Active Not Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT07285044Phase 2Recruiting

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

NCT04879940Phase 2Active Not RecruitingPrimary

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

NCT04484818Phase 3Active Not RecruitingPrimary

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

NCT06957691Phase 2Recruiting

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT00002540Not ApplicableActive Not RecruitingPrimary

Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)

NCT05438563Not ApplicableRecruitingPrimary

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer

NCT04254133Enrolling By InvitationPrimary

Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study

NCT03697148Not ApplicableActive Not RecruitingPrimary

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer

NCT04457232Phase 1Active Not Recruiting

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

NCT04597359Phase 2Active Not RecruitingPrimary

To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring

NCT04857502Early Phase 1RecruitingPrimary

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

NCT07218718Not ApplicableRecruitingPrimary

Oral Cryotherapy to Decrease Taste Changes in Prostate Cancer Patients Receiving Taxane Chemotherapy

NCT06865768Phase 2RecruitingPrimary

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

NCT05067777Phase 2TerminatedPrimary

Massage for Prostate Cancer-Related Fatigue (mPROSTATE)

NCT06995898Not ApplicableRecruiting

The Vanguard Study: Testing a New Way to Screen for Cancer

NCT04765150RecruitingPrimary

Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

NCT07118176Phase 1Active Not Recruiting

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT04788277Active Not RecruitingPrimary

Investigation Into Detection of Prostate Cancer Using Voided Urine (Prostate VPAC)

NCT04947254Phase 2RecruitingPrimary

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Scroll to load more

Research Network

Activity Timeline